https://orcid.org/0000-0002-2422-8486
References
- Azmi S, Petropoulos IN, Ferdousi M, Ponirakis G, Alam U, Malik RA. An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy. F1000Research. 2019;8:186. doi:10.12688/f1000research.17118.1
- D’Souza M, Barman R, Joseph A, Abd-Elsayed A. Evidence-based treatment of painful Diabetic Neuropathy: a Systematic Review. Curr Pain Headache Rep. 2022;26(8):583–594. doi:10.1007/s11916-022-01061-7
- Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The COMBO-DN study a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616–2625. doi:10.1016/j.pain.2013.05.043
- Alleman CJM, Westerhout KY, Hensen M, et al. Humanistic and economic burden of painful diabetic neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015;109(2):215–225. doi:10.1016/j.diabres.2015.04.031
- Bevilacqua M, Barrella M, Toscano R, et al. Disturbances of vasomotion in diabetic (type 2) neuropathy: increase of vascular endothelial growth factor, elicitation of sympathetic efflux and synchronization of vascular flow (vasomotion) during frequency modulated neural stimulation (FREMS). 86th Annual Meeting of the Endocrine Society; 2004:321.
- Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005;48:817–823. doi:10.1007/s00125-005-1734-2
- Bouhassira D, Attal N, Fermanian J, et al. Development and Validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248–257. doi:10.1016/j.pain.2003.12.024
- Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220. doi:10.1097/00005650-200503000-00003
- Bosi E, Bax G, Scionti L, et al.; FREMS European Trial Study Group. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled trial. Diabetologia. 2013;56(3):465–475. doi:10.1007/s00125-012-2795-7
- Emerson GG, Segal SS. Electrical activation of endothelium evokes vasodilatation and hyperpolarization along hamster feed arteries. Am J Physiol Heart Circ Physiol. 2001;280:H160–H167.
- Bocchi L, Evangelisti A, Barella M, Scatizzi L, Bevilacua M. Recovery of 0,1 Hz microvascular skin flow in dysautonomic diabetic (type 2) neuropathy by using Frequency Rhythmic Electrical Modulation System (FREMS). Med Eng Phys. 2010;32:407–413. doi:10.1016/j.medengphy.2010.02.004
- Bevilacqua M, Dominguez LJ, Barella M, Barbagallo M. Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy. J Endocrinol Invest. 2007;30:944–947. doi:10.1007/BF03349242
- Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–638. doi:10.1016/j.pain.2004.05.001
- Butler S, Eek D, Ring L, Gordon A, Karlsten R. The utility/futility of medications for neuropathic pain – an observational study. Scan J Pain. 2019;19(2):327–335. doi:10.1515/sjpain-2018-0317
- Crasto W, Altaf Q-A, Selvaraj DR, et al. Frequency Rhythmic Electrical Modulation System (FREMS) to alleviate painful diabetic peripheral neuropathy: a pilot, randomised controlled trial (The FREMSTOP study). Diabet Med. 2022;39:e14710. doi:10.1111/dme.14710